Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. - Wikidata - awgldk - TriplyDB

Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.

Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.

http://www.wikidata.org/entity/Q43109280

about

Gene therapy in Parkinson's disease: rationale and current status Available and emerging treatments for Parkinson's disease: a review Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives Cell Therapy for Parkinson's Disease: New Hope from Reprogramming Technologies Parkinson's disease: gene therapies Patient-specific induced pluripotent stem cells in neurological disease modeling: the importance of nonhuman primate models Parkinson's disease gene therapy: success by design meets failure by efficacy Treating Parkinson's disease in the 21st century: can stem cell transplantation compete?Current Experimental Studies of Gene Therapy in Parkinson's Disease Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinson's disease IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates A new quantitative rating scale for dyskinesia in nonhuman primates.Rescue of severe infantile hypophosphatasia mice by AAV-mediated sustained expression of soluble alkaline phosphatase Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Critical aspects of clinical trial design for novel cell and gene therapies.Synaptic pathology and therapeutic repair in adult retinoschisis mouse by AAV-RS1 transfer.Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease Neurotensin-Conjugated Reduced Graphene Oxide with Multi-Stage Near-Infrared-Triggered Synergic Targeted Neuron Gene Transfection In Vitro and In Vivo for Neurodegenerative Disease Therapy.Retinal Gene Therapy: Current Progress and Future Prospects.Serotype-dependent transduction efficiencies of recombinant adeno-associated viral vectors in monkey neocortex Two decades of clinical gene therapy--success is finally mounting Focusing brain therapeutic interventions in space and time for Parkinson's disease.Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates.Direct and retrograde transduction of nigral neurons with AAV6, 8, and 9 and intraneuronal persistence of viral particles Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors.Pervasive supply of therapeutic lysosomal enzymes in the CNS of normal and Krabbe-affected non-human primates by intracerebral lentiviral gene therapy Gene-based therapies in Parkinson's disease.Large-scale chondroitin sulfate proteoglycan digestion with chondroitinase gene therapy leads to reduced pathology and modulates macrophage phenotype following spinal cord contusion injury.Gene therapy: a viable therapeutic strategy for Parkinson's disease?Gene therapy for Parkinson's disease: where are we now and where are we going?New non-oral drug delivery systems for Parkinson's disease treatment.Synthetic biology with surgical precision: targeted reengineering of signaling proteins.Viral vectors and delivery strategies for CNS gene therapy.A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.New developments in lentiviral vector design, production and purification.Progress in gene therapy for neurological disorders.Gene therapy for Parkinson's disease: state-of-the-art treatments for neurodegenerative disease.Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications Regenerative medicine for Parkinson's disease.

P2860

Q22241423-7679CE67-8DB5-429B-B13E-07733C5DC215 Q24633444-8BF7B50C-103B-4471-8C00-6B072A32B0B4 Q26747508-8FA045B2-EE61-46D7-9F24-C0C43CA7AF17 Q26776041-BCC3474C-708F-4254-8998-79FB96A1A1CC Q26824184-F16A8968-3AA8-4586-A4C6-84FAF1C928A3 Q26825524-FE624D81-7EA4-40F6-96A2-29B034183EEB Q26851325-B9037F2C-1CCA-41D9-9865-8204AD7C54AC Q27024152-BDFD177E-7D32-42B3-9A61-2710F61F386A Q33627771-64573256-4317-4041-8329-B8331D3E2109 Q34473323-5E5BD4E5-5474-4753-997F-D638F30D4811 Q34542164-DC39F114-7E12-47A2-AFFF-B0D8374015FD Q34771498-54F3F056-FF2F-4921-89E6-10B1F7AC5DD3 Q35575693-49A5425F-88EC-4302-B617-F130FCF2C4A4 Q35589979-BFAE92A5-5F48-40A1-A21F-8E39669084DE Q35614156-E9837FA7-FC22-4BAA-A0A6-360C40FB4647 Q35664438-067DDDD9-692A-4DB0-938F-FE9E7BD1648B Q36040298-D168BB5E-8FA3-4BD4-B9A1-2E1989A671C6 Q36085361-933EA932-859C-4D93-A2E7-3C010768B778 Q36180141-2AE62DE6-2EC7-408F-BF85-007896799C73 Q36306263-D63E2EFF-ED9F-4CEB-9868-CE15174E815A Q36508670-ED357BBD-D5DA-4C54-A5BD-5D6AAE25E67F Q36652351-FE355FBD-4D55-4AB8-AF4A-3B79A499C786 Q36745293-84C47A4D-EB40-4012-9D2A-0B1AFCC2DC3B Q36920437-2FF73655-D0DE-442F-B87A-B511ADF5C1CB Q36945745-C232A04F-82A1-400F-BEA1-6B40BB829EE9 Q36983576-1A2E230D-8D5F-48E7-B6ED-916D674D2217 Q37453594-B74BA10F-27BF-41B0-9EB7-C1F292805C04 Q37506503-A2A1A6B4-6AFC-4157-9029-ED767E4327C0 Q37679296-13DBEA6D-F7CF-4469-BA48-B2EA74B95EEE Q37801855-A6AEF6B4-B91F-4AA3-B099-5FA22FEFF444 Q37810994-04EB026D-A7BF-4F5A-946D-74D873564059 Q37840165-23B5DC86-DBB5-45DB-9E68-31F9090403A3 Q38016028-D721ABC6-0802-44C4-94FB-7E9AEAB3DCC2 Q38029645-5B6FF2B6-574A-4DB9-BB7A-6ADB415C3C30 Q38075068-937D32F5-071A-465B-B25D-947D7968B65E Q38099382-A55AF579-7240-46BC-A76D-01A0BC6D9F92 Q38100997-4D44E4D9-063A-4B8B-B97E-691685A225A7 Q38112216-147653AA-F1DF-464B-B1B2-334AED5DE2BE Q38166648-2494F88A-70A4-4F4F-898F-7FDFB04B260E Q38369065-9862DDAB-C6BD-4BB9-B4D2-10310A351FD6

P2860

Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.

http://www.wikidata.org/entity/Q43109280

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Dopamine gene therapy for Park ...... without associated dyskinesia.

@en

Dopamine gene therapy for Park ...... without associated dyskinesia.

@nl

type

label

Dopamine gene therapy for Park ...... without associated dyskinesia.

@en

Dopamine gene therapy for Park ...... without associated dyskinesia.

@nl

prefLabel

Dopamine gene therapy for Park ...... without associated dyskinesia.

@en

Dopamine gene therapy for Park ...... without associated dyskinesia.

@nl

P1433

Q43109280-71C3EA63-A37E-4CA9-91A1-DE3C615E8976

P1476

Q43109280-8C266B19-025D-49F9-8C2E-C3CBC9AB95C1

P2093

Q43109280-1F645221-087E-4AAD-A419-2B3AAFC79845

Q43109280-294F1AB6-3CA4-435D-B187-FEC7B51991D1

Q43109280-55FF2206-0F46-4A11-81A4-A7E33FEBFB4F

Q43109280-5840B618-A8DE-44E1-B7FC-2ADA61E74C68

Q43109280-77904041-17B8-4995-9056-C8B7A182CFC7

Q43109280-8353E710-7FE2-43EE-8A08-924108766B8E

Q43109280-AB2196E3-6E5B-466F-9775-2194B185006C

Q43109280-C520B530-725B-473F-B7D0-21697694EF63

Q43109280-C83D32E8-A072-47D5-861B-2A7F82B2B25D

Q43109280-DA73791F-8F13-4050-9062-F0611B2D6D6B

P2860

Q43109280-03A238CC-35E5-400B-8852-33DB7EF0B66A

Q43109280-03A6EEE3-D029-4E55-B24B-973E66B1A44C

Q43109280-04C558E1-9B3E-42AD-92AD-2E7D08143BB9

Q43109280-0A781181-3316-470D-B324-D120D2FAD703

Q43109280-10C10429-2DE4-4543-96C0-6E331AD2751F

Q43109280-185FA130-064E-458F-BF17-9CFA1CDD30B5

Q43109280-1C0A4F66-B3EE-4314-B760-AC04F4C33A95

Q43109280-1C6CB89D-1AD3-445E-9EF4-9E86831735CF

Q43109280-20ED7FFB-B312-4490-A1D0-46CDE5ABFFC9

Q43109280-2DB8431E-90CE-43E8-9AE5-D07194D4D7BA

P304

Q43109280-03C8CA4C-F04C-48A6-BDB4-CA8609D835C7

P31

Q43109280-2E7255E3-BCE7-460B-83C9-9A5C110D1B97

P356

Q43109280-7952C712-F85C-4E92-8F0E-C4633348815D

P407

Q43109280-7241A7B2-7135-4018-A760-EA090891025B

P433

Q43109280-34E723AA-7438-41B1-B5EE-5C9923AE852E

P478

Q43109280-0CD7BCFE-A8D6-4B89-84F1-8BDD579A15E7

P50

Q43109280-13143D28-9561-46E1-B0E2-782E798DA30D

Q43109280-34FCF2F5-F099-463B-AA89-085B8BA0AC3E

Q43109280-4D52BBC3-B155-4DAA-B0B0-9E7B0279CDAC

Q43109280-5F25A380-E924-4289-B676-898CD59EF425

Q43109280-CCCED4C0-345A-48E9-B63D-CB0B8DD4A640

Q43109280-F5B48B50-912A-4C79-A7EE-E85950A1ACCD

P577

Q43109280-694AFDFF-C64D-4925-B306-E0748B1B842C

P5875

Q43109280-804C2AE1-91F0-4A14-977B-584E7C9D5A03

P698

Q43109280-37003E5D-1233-43B1-98EE-D4CE607990DA

P921

Q43109280-364F3DB7-C2E1-448D-A30B-D4F04E52A5EA

Q43109280-5EA9D043-90EC-48B8-8D65-08033C84306E

Q43109280-6f50c670-e593-4556-8d24-36c8131f0abd

Q43109280-DE7BB407-0516-45C0-A89E-3B153AE41608

P356

SCITRANSLMED.3000130

P1433

Science Translational Medicine

P1476

Dopamine gene therapy for Park ...... without associated dyskinesia

@en

P2093

Caroline Jan

http://www.w3.org/2001/XMLSchema#string

Denise M Day

http://www.w3.org/2001/XMLSchema#string

G Scott Ralph

http://www.w3.org/2001/XMLSchema#string

James E Miskin

http://www.w3.org/2001/XMLSchema#string

Kyriacos A Mitrophanous

http://www.w3.org/2001/XMLSchema#string

Masahiro Shin

http://www.w3.org/2001/XMLSchema#string

Nicholas D Mazarakis

http://www.w3.org/2001/XMLSchema#string

Philippe Hantraye

http://www.w3.org/2001/XMLSchema#string

Sabrina Boulet

http://www.w3.org/2001/XMLSchema#string

Stéphane Palfi

http://www.w3.org/2001/XMLSchema#string

P2860

Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter

Treatment interventions for Parkinson's disease: an evidence based assessment

Optical deconstruction of parkinsonian neural circuitry

Parkinsonism: onset, progression and mortality

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

Primate models of movement disorders of basal ganglia origin

Parkinson's disease. First of two parts

Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer

Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?

Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.

P304

2ra4

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3000130

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Emmanuel Brouillet

Gilles Bonvento

Anne-Sophie Hérard

P577

2009-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43023133

http://www.w3.org/2001/XMLSchema#string

P698

20368163

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease